<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170426</url>
  </required_header>
  <id_info>
    <org_study_id>CTX0019-001</org_study_id>
    <nct_id>NCT04170426</nct_id>
  </id_info>
  <brief_title>Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis</brief_title>
  <official_title>Phase 1/2a Clinical Study for Subjects With Rheumatoid Arthritis (RA) Using Multiple Dose Intravenous Infusions of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltex Therapeutics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltex Therapeutics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigational new drug clinical trial for combined Phase 1 dose escalation study&#xD;
      and Phase 2a randomized, placebo controlled and double blinded study using intravenous&#xD;
      injection of autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis&#xD;
      patients. All subjects are monitored for safety (adverse events/severe adverse events) and&#xD;
      evaluated for RAPID3, DAS28 and ACR20 regarding AdMSCs up to 52 weeks study duration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients who failed disease-modifying antirheumatic drug (DMARDs).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events and Sever Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>The total number of adverse events and severe adverse events related and non-related with AdMSCs will be recorded to indicate the safety and tolerability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Celltex AdMSCs</measure>
    <time_frame>52 weeks</time_frame>
    <description>Proportion of ACR 20 patients (swollen joints, tender joints, patient assessment of pain, RAPID3, DAS28-CRP and blood inflammatory panel tests) in comparison between baseline and post-treatment follow-up data.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Phase 1 ARM 0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 ARM 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 subjects receive three doses of 2.0-2.86×10^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 ARM 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous adipose derived stem cells</intervention_name>
    <description>Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue</description>
    <arm_group_label>Phase 1 ARM 0</arm_group_label>
    <arm_group_label>Phase 2 ARM 1</arm_group_label>
    <arm_group_label>Phase 2 ARM 2</arm_group_label>
    <other_name>Celltex-AdMSCs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must pass communicable disease screen tests for HIV, syphilis, Hepatitis B and C&#xD;
             Consistent with American Rheumatism Association-European League Against Rheumatism&#xD;
             (ACR/EULAR) 2010 rheumatoid arthritis classification criteria&#xD;
&#xD;
          -  Active Rheumatoid Arthritis, see RA functional status of class I-IV&#xD;
&#xD;
          -  Patients must meet at least one of the following: &gt; 6 swollen joints and ≥ 6 involved&#xD;
             joints (tenderness, swelling, deformity, pain on motion, or decreased motion) and&#xD;
             morning stiffness ≥ 45 minutes based on 68 joint count.&#xD;
&#xD;
          -  Patients must also meet at least one of the following: rheumatoid factor (RF) &gt; 15&#xD;
             IU/mL or &gt; 1:16, C-reactive protein (CRP) &gt; 2.0 mg/dL, Erythrocyte Sedimentation Rate&#xD;
             (ESR) &gt; 30 mm/hour, and anti-cyclic citrullinated protein (Anti-CCP) &gt; 20 U/mL, TNFα &gt;&#xD;
             2.8 pg/mL.&#xD;
&#xD;
          -  Patients must have failed anti-rheumatoid drug due to adverse event or inefficacy for&#xD;
             at least 12 week and at least 4 weeks on stable dose of methotrexate ≤ 25 mg/week, or&#xD;
             leflunomide ≤ 20 mg/day, or sulfasalazine ≤ 3 g/day, or steroids (Prednisone &lt;10&#xD;
             mg/day).&#xD;
&#xD;
          -  For other medications, patients must be on the stable dose for at least 4 weeks prior&#xD;
             to study entry in order to preclude changes to patient medication while participating&#xD;
             on the study to ensure that a medication change could become a confounding factor in&#xD;
             data interpretation.&#xD;
&#xD;
          -  All patients must be clinically stable with no significant changes in health status a&#xD;
             minimum of at least 4 weeks prior to randomization and confirming patient eligibility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or prior to treatment&#xD;
&#xD;
               -  Participation in another clinical study (with use of another Investigational&#xD;
                  Medical Product) within 3 months prior to study treatment start&#xD;
&#xD;
               -  Evidence of immune suppression related to prior/current therapy&#xD;
&#xD;
               -  &gt; 10% change in delivered monthly dose of anti-rheumatoid medications within 4&#xD;
                  weeks prior to this stem cell infusion&#xD;
&#xD;
               -  Use of a new or additional anti-rheumatoid medication within 6 weeks prior to&#xD;
                  this stem cell infusion&#xD;
&#xD;
               -  Use of other stem cell therapy within 12 weeks prior to this stem cell therapy&#xD;
&#xD;
               -  Unwillingness or inability to comply with study procedures&#xD;
&#xD;
          2. Concurrent Conditions&#xD;
&#xD;
               -  Clinically active malignant disease&#xD;
&#xD;
               -  Severe bladder or thrombotic disorder&#xD;
&#xD;
               -  History of known pulmonary embolism or known secondary anti-phospholipid syndrome&#xD;
&#xD;
               -  Known or suspected hypersensitivity to any components used to culture or store&#xD;
                  the AdMSCs, e.g. sulfur or sulfonamide&#xD;
&#xD;
               -  Known or suspected antibodies to any components used to culture the AdMSCs, e.g.&#xD;
                  BSA and sulfur containing products (e.g., DMSO)&#xD;
&#xD;
               -  Active infection at time of planned study treatment start&#xD;
&#xD;
               -  Age related pathology likely to inhibit study participation or completion&#xD;
&#xD;
               -  Major trauma or surgery within 14 days of study treatment start&#xD;
&#xD;
               -  Mental condition rendering the subject (or the subject's legally acceptable&#xD;
                  representative[s]) unable to understand the nature, scope and possible&#xD;
                  consequences of the study&#xD;
&#xD;
               -  Alcohol, drug, or medication abuse within one year before study treatment start&#xD;
&#xD;
               -  Any condition that, in the Investigator's opinion, is likely to interfere with&#xD;
                  evaluation of the AdMSC therapy or satisfactory conduct of the study&#xD;
&#xD;
               -  Irreversible severe end organ failure, such as heart failure/attack, stroke,&#xD;
                  liver and renal failure&#xD;
&#xD;
               -  Heavy smokers, bed-bound patients, patients or family history with&#xD;
                  hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden,&#xD;
                  prothrombin gene mutation, dysfibrinogenemia, etc.&#xD;
&#xD;
          3. Laboratory Parameters&#xD;
&#xD;
               -  Hepatic impairment, defined as any of ALT, AST, LDH or bilirubin &gt; 2 x the upper&#xD;
                  limit of normal (ULN) range according to local laboratory standards&#xD;
&#xD;
               -  Renal impairment, defined as serum creatinine &gt; 133 mmol/L (1.5 mg/dL)&#xD;
&#xD;
               -  Positive virology/serology for human immunodeficiency virus (HIV), hepatitis B&#xD;
                  (HBsAg positive), hepatitis C and/or syphilis&#xD;
&#xD;
          4. Pregnancy / contraception&#xD;
&#xD;
               -  Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice&#xD;
                  birth control during participation in the study duration, unless surgically&#xD;
                  sterilized or postmenopausal during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek W Guillory, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Root Causes Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally McGahee</last_name>
    <phone>7135546847</phone>
    <email>smcgahee@celltexbank.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

